Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International : DiviTum®TKa included in new UK breast cancer study

11/23/2020 | 02:01am EST

DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring during treatment with a CDK4/6 inhibitor, which in combination with an aromatase inhibitor is considered standard of care for this subgroup of patients.

The hypothesis is that routine imaging can be delayed until predefined levels of biomarker progression is detected. The aim is to establish a biomarker algorithm, which includes DiviTum®TKa and other biomarkers, that safely can define response to therapy or stable disease and also predict disease progression. DiviTum®TKa accurately correlates with disease status and can be a useful tool in this respect.

“Our study aims to optimise the monitoring of patients, utilising circulating biomarkers to avoid unnecessary imaging exams. We have chosen to include DiviTum for analysis of TK activity as accurate measurements of cell proliferation rate is likely to be important in this setting. DiviTum has documented ability to provide precise prognostic and efficacy monitoring capabilities and we look forward to see results that can potentially enhance monitoring options in metastatic breast cancer”, said Dr. Sacha J. Howell, FRCP, PhD and Principal Investigator of the study.

The study will collect blood samples before treatment initiation and during therapy with the aim to include approximately 100 patients in the UK and Sweden.

“We look forward to collaborate with Christie Hospital in Manchester and other clinics in the study in UK and Sweden in this exciting study, where we believe the results can potentially contribute to a more personalised approach also regarding radiological follow-up for metastatic breast cancer patients”, said Anders Rylander, CEO of Biovica.

Link to study NCT04597580

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTum®TK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTum®TKa included in new UK breast cancer study
AQ
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTum®TKa r..
AQ
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTum®TKa as an early an..
AQ
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
2020BIOVICA INTERNATIONAL : DiviTum®TKa Monitoring Capabilities Confirmed in SWOG St..
AQ
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
2020BIOVICA INTERNATIONAL : FDA resource reallocation impacts DiviTum®TKa timeline
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,58 M -4,58 M
Net cash 2021 134 M 15,9 M 15,9 M
P/E ratio 2021 -33,3x
Yield 2021 -
Capitalization 1 315 M 157 M 156 M
EV / Sales 2021 394x
EV / Sales 2022 27,7x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Technical analysis trends BIOVICA INTERNATIONAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 46,50 SEK
Spread / Highest target 122%
Spread / Average Target 44,1%
Spread / Lowest Target -33,3%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors